Shareholding disclosure

Credit Suisse Funds AG

Declared position

8.06%

Threshold

Crossed upwards

Timeline

Published

10.04.2018

Transaction

28.03.2018

Transfer date

29.03.2018

Voting rights breakdown

Voting rights acquired8.06%

Voting rights sold0%

Below threshold0%

Notice details

CategoryCollective investment vehicle

ExchangeXSWX

Notification ID

TCI4500027

Beneficial owner

Credit Suisse Funds AG

Declared address

Credit Suisse Funds AG, Zurich

Open shareholder profile Open company profile

Back to the feed

Shareholding disclosure

Credit Suisse Funds AG

Addex Therapeutics Ltd10.04.2018TCI4500027

Disclosure summary

Credit Suisse Funds AG disclosed a holding in Addex Therapeutics Ltd on the acquisition side, published by SIX Exchange Regulation on 10.04.2018, at 8.06% of voting rights. Notice category: Collective investment vehicle.

Disclosed position

8.06%

Voting rights acquired

Voting rights acquired8.06%

Voting rights sold0%

Below threshold0%

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open

Disclosure detail

Credit Suisse Funds AG disclosed a holding in Addex Therapeutics Ltd, published on 10.04.2018.

Publication date10.04.2018

Transaction date28.03.2018

Transfer date29.03.2018

Issuing companyAddex Therapeutics Ltd

Beneficial ownerCredit Suisse Funds AG

Declared addressCredit Suisse Funds AG, Zurich

CategoryCollective investment vehicle

Voting rights acquired8.06%

Voting rights sold0%

Below threshold0%

ExchangeXSWX

Notification IDTCI4500027

Commercial register

CHE-102.923.465

Struck off the register · 03.05.2024

Zefix record

Source: SIX Exchange Regulation · Publication date: 10.04.2018

These figures aggregate public disclosures. They are not investment advice.

insider24.ch

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open